This platform was used to develop a quantitative assay for the EGFR protein in FFPE tissue samples taken from patients with NSCLC enrolled in a phase II neoadjuvant trial of the EGFR inhibitor, gefitinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.